JP7802651B2 - 抗ｎａｍｐｔ抗体及びその用途 - Google Patents

抗ｎａｍｐｔ抗体及びその用途

Info

Publication number
JP7802651B2
JP7802651B2 JP2022507630A JP2022507630A JP7802651B2 JP 7802651 B2 JP7802651 B2 JP 7802651B2 JP 2022507630 A JP2022507630 A JP 2022507630A JP 2022507630 A JP2022507630 A JP 2022507630A JP 7802651 B2 JP7802651 B2 JP 7802651B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022507630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543658A5 (https=
JP2022543658A (ja
Inventor
ジー．エヌ． ガルシア ジョー
マッキャン ダラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqualung Therapeutics Corp
Original Assignee
Aqualung Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqualung Therapeutics Corp filed Critical Aqualung Therapeutics Corp
Publication of JP2022543658A publication Critical patent/JP2022543658A/ja
Publication of JP2022543658A5 publication Critical patent/JP2022543658A5/ja
Priority to JP2025139120A priority Critical patent/JP2025176044A/ja
Application granted granted Critical
Publication of JP7802651B2 publication Critical patent/JP7802651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022507630A 2019-08-07 2020-08-07 抗ｎａｍｐｔ抗体及びその用途 Active JP7802651B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139120A JP2025176044A (ja) 2019-08-07 2025-08-22 抗ｎａｍｐｔ抗体及びその用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962883952P 2019-08-07 2019-08-07
US62/883,952 2019-08-07
PCT/US2020/045511 WO2021026508A1 (en) 2019-08-07 2020-08-07 Anti-nampt antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139120A Division JP2025176044A (ja) 2019-08-07 2025-08-22 抗ｎａｍｐｔ抗体及びその用途

Publications (3)

Publication Number Publication Date
JP2022543658A JP2022543658A (ja) 2022-10-13
JP2022543658A5 JP2022543658A5 (https=) 2023-08-16
JP7802651B2 true JP7802651B2 (ja) 2026-01-20

Family

ID=74503750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507630A Active JP7802651B2 (ja) 2019-08-07 2020-08-07 抗ｎａｍｐｔ抗体及びその用途
JP2025139120A Pending JP2025176044A (ja) 2019-08-07 2025-08-22 抗ｎａｍｐｔ抗体及びその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139120A Pending JP2025176044A (ja) 2019-08-07 2025-08-22 抗ｎａｍｐｔ抗体及びその用途

Country Status (7)

Country Link
US (3) US11142586B2 (https=)
EP (1) EP4010368A4 (https=)
JP (2) JP7802651B2 (https=)
CN (1) CN114929738B (https=)
AU (1) AU2020325315A1 (https=)
CA (1) CA3147020A1 (https=)
WO (1) WO2021026508A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN113614535B (zh) 2018-10-31 2024-08-16 亚利桑那大学评议会 用于辐射诱导的肺损伤的生物标志物和使用方法
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2021195265A1 (en) * 2020-03-24 2021-09-30 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN117815243B (zh) * 2023-12-29 2025-01-24 四川大学华西医院 一种化合物在制备治疗肝纤维化的药物以及nampt抑制剂中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020364A1 (en) 2009-07-23 2011-01-27 Garcia Joe G N Methods and compositions involving pbef inhibitors for lung inflammation conditions and diseases
WO2017041114A2 (en) 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
WO2018191751A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480059C (en) 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
WO2004050708A2 (en) 2002-11-29 2004-06-17 Rsr Limited Antibody for the thyrotropin receptor and uses thereof
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CN104684906B (zh) * 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
AU2015357543B2 (en) * 2014-12-05 2021-10-21 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
PL3560953T3 (pl) * 2014-12-24 2024-05-13 Autolus Limited Komórka
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
CN105055412B (zh) * 2015-08-20 2018-06-19 四川大学 Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途
JP7490565B2 (ja) * 2017-12-29 2024-05-27 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020364A1 (en) 2009-07-23 2011-01-27 Garcia Joe G N Methods and compositions involving pbef inhibitors for lung inflammation conditions and diseases
WO2017041114A2 (en) 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
WO2018191751A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis

Also Published As

Publication number Publication date
EP4010368A1 (en) 2022-06-15
JP2025176044A (ja) 2025-12-03
CN114929738B (zh) 2026-01-02
US11466099B2 (en) 2022-10-11
AU2020325315A1 (en) 2022-03-24
CA3147020A1 (en) 2021-02-11
CN114929738A (zh) 2022-08-19
JP2022543658A (ja) 2022-10-13
US11142586B2 (en) 2021-10-12
US20230220113A1 (en) 2023-07-13
US20210070883A1 (en) 2021-03-11
WO2021026508A1 (en) 2021-02-11
US20220056152A1 (en) 2022-02-24
EP4010368A4 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
JP7802651B2 (ja) 抗ｎａｍｐｔ抗体及びその用途
US11220544B2 (en) Anti-CD166 antibodies and uses thereof
RU2598711C2 (ru) Антитело к противоопухолевому антигену и способы применения
US12286471B2 (en) Inhibitors of complement factor H
CN101903044A (zh) 对人铁调素具有特异性的抗原结合蛋白
JP2017537084A (ja) 抗エンドグリン抗体及びその用途
JP2023548535A (ja) インターロイキン３６ｒを標的とする抗体、その調製法と応用
BR112020016469A2 (pt) Anticorpos do receptor anti-folato 1 e seus usos
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
US20250346655A1 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
JP2021500895A (ja) Ａｌｋ７結合タンパク質およびその使用
CN103201291B (zh) 抗单链iv型胶原多肽抗体和包含其的用于诊断、预防或治疗肿瘤的药物或药剂
US20240384005A1 (en) Anti-ngly-1 antibodies and methods of use
US11192948B2 (en) Compositions and methods for inhibiting cancer stem cells
HK40080584A (en) Anti-nampt antibodies and uses thereof
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
US20250011405A1 (en) Treatment and diagnosis of diseases associated to pathogenic fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260107

R150 Certificate of patent or registration of utility model

Ref document number: 7802651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150